Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, AND -A12 tumor antigens: Implication in a broad-spectrum tumor immunotherapy

Journal of Immunology

Volumn 169, Issue 1, 2002, Pages 575-580

  Graff Dubois, Stéphanie ^a   Faure, Olivier ^a   Gross, David Alexandre ^a   Alves, Pedro ^a   Scardino, Antonio ^a   Chouaib, Salem ^a   Lemonnier, François A ^a   Kosmatopoulos, Kostas ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; HLA A ANTIGEN; PEPTIDE P248V9; RNA; RNA DIRECTED DNA POLYMERASE; TELOMERASE; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG ANTIGENICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONONUCLEAR CELL; MOUSE; MULTIGENE FAMILY; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0036644634     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.1.575     Document Type: Article

References (42)

1. Genes coding for tumor antigens recognized by cytolytic T lymphocytes
2. Human tumor antigens recognized by T cells
3. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes
4. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans
5. Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes
6. Tolerance to p53 by A2.1 restricted cytotoxic T lymphocytes
7. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self-tolerance on the TCR repertoire
8. Structure, chromosomal localization, and expression of 12 genes of the MAGE family
9. Expression of MAGE-1, MAGE-2 and MAGE-3 genes in human gastric carcinomas: Lack of evidence for cytotoxic effects in cases with simultaneous expression of MAGE-3 and HLA-A2
10. MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma
11. T cell defined tumor antigens
12. Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder
13. MAGE-A gene expression pattern in primary breast cancer
14. Expression of MAGE genes in osteosarcoma
15. Expression of the melanoma encoding gene in human lung cancer
16. Expression of the MAGE-1, -2, -3, -4, and -6 genes in nonsquamous cell carcinoma lesions of the head and neck
17. Expression spectrum of melanoma antigen encoding gene family members in colorectal carcinoma
18. Expression of MAGE genes in renal cell carcinoma
19. MAGE, BAGE and GAGE: Tumor antigen expression in benign and malignant ovarian tissue
20. Expression of the MAGE gene family in human hepatocellular carcinoma
21. Serum MAGE-4 protein in ovarian cancer patients
22. Expression of MAGE gene family in lung cancer
23. Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family
24. 2m double knockout mice
25. A highly sensitive cell line WEHI 164 clone 13 for measuring cytotoxic factor/tumor necrosis factor from human monocytes
26. Expression of MAGE genes by non-small-cell lung carcinomas
27. CDNA and protein characterization of human MAGE-10
28. Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12
29. A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: Implication in the identification of cryptic tumor epitopes
30. Amino acid identity and/or position determines the proteasomal cleavage of the HLAA*0201 restricted peptide tumor antigen MAGE-3 271-279
31. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma
32. Tumor escape from immune recognition: Lethal recurrent melanoma in a patient associated with down-regulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen
33. Quantitative evaluation of the expression of MAGE genes in tumors by limiting dilution of cDNA libraries
34. High-avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy
35. The antigenic identity of peptide MHC complexes: A comparison of the conformations of five viral peptides presented by HLA-A2
36. Improved induction of melanoma-reactive CTL with peptides from melanoma antigens gp100 modified at HLAA*0201-binding residues
37. Analogues of CTL epitopes with improved MHC class I binding capacity elicit anti-melanoma CTL recognizing the wild type epitope
38. Enhanced generation of specific tumor reactive CTL in vitro by selected Melan-A/MART-I immunodominant peptide analogs
39. Identification of new epitopes from four different tumor-associated antigens: Recognition of naturally processed epitopes correlates with HLA-A*0201 binding affinity
40. Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor specific MAGE-2 gene product
41. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes
42. A MAGE-A1 HLAA*0201 epitope identified by mass spectrometry